BTG

Contact
btgplc.com
+442075750000

BTG plc

10 Fleet Place, Limeburner Lane
EC4M 7SB London
United Kingdom
+442075750000
btgplc.com
Contact
Profile Products News
Contact

About BTG

BTG is a growing life sciences company focused on the development and commercialisation of pharmaceuticals principally targeting neuroscience and oncology.

Read more about BTG
Facts about BTG
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of BTG

Product portfolio

Show all

News about BTG

BTG

08-Dec-2008 | business & finance

BTG plc: Completion of the Acquisition of Protherics PLC

BTG plc announced that all the conditions to its recommended offer for Protherics PLC have been satisfied and the Acquisition has therefore been completed ...

Read news
BTG

11-Nov-2008 | business & finance

BTG licenses novel anticancer compound to Onyx Pharmaceuticals

BTG to receive $13m upfront plus potential milestones of up to $307m and sales royalties

Read news
BTG

08-Aug-2008 | research and development

BTG plc: Tolerx initiates dosing of otelixizumab in a phase III clinical trial in type 1 diabetes

Tolerx to pay milestone of $7.5 million to BTG

Read news
BTG

25-Jul-2008 | research and development

BTG: Study Shows Abiraterone Can Successfully Treat Aggressive, Chemotherapy-Resistant Prostate Cancer

BTG plc notes the publication of a new study in the Journal of Clinical Oncology showing that abiraterone caused significant tumour shrinkage and reduction ...

Read news
BTG

09-Jun-2008 | business & finance

BTG plc: Acquisition of Protez Pharmaceuticals by Novartis

BTG to receive approximately $5 million in respect of its shareholding in Protez upon close of transaction with further potential payments

Read news
BTG

14-Apr-2008 | research and development

BTG Reports Positive Results from First Study Investigating BGC20-0166 in Obstructive Sleep Apnoea Patients

Novel Combination Therapy Shown to be Well-Tolerated and to Reduce the Apnoea-Hypopnoea Index in OSA Patients

Read news
BTG

10-Mar-2008 | research and development

BTG Initiates Clinical Study of Novel Multiple Sclerosis Treatment

BTG plc announced that dosing has commenced in a Phase I clinical study of BGC20-0134, a potential treatment for multiple sclerosis. The randomised, double ...

Read news
BTG

01-Feb-2008 | research and development

BTG plc commences first clinical study of novel migraine treatment

BTG plc announced that BGC20-1531, a potential treatment for migraine headaches, has commenced clinical development. Dosing has begun in a randomised, ...

Read news
Show more news about BTG

Here you will find BTG plc